Effect of Vericiguat on Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45% (NCT06321094) | Clinical Trial Compass
CompletedNot Applicable
Effect of Vericiguat on Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45%
China149 participantsStarted 2024-01-31
Plain-language summary
Investigators evaluate whether differences exsit in acute coronary syndrome（ACS） patients with ejection \<45% between participants who take vericiguat regularly and those who donot.
Who can participate
Age range18 Years – 90 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 1.Provide written informed consent for the trial.
* 2.Has acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction \[NSTEMI\], or ST elevation myocardial infarction \[STEMI\]) or coronary revascularization (coronary artery bypass grafting \[CABG\] or percutaneous coronary intervention \[PCI\]).
* 3.ejection fraction \<45%.
* 4.Be male or female, aged greater than18 and less than 90 on the day of signing informed consent.
Exclusion Criteria.
* 1.SBP\<100mmHg.
* 2.Is pregnant or breastfeeding or plans to become pregnant or to breastfeed during the course of the trial.
* 3.Has severe hepatic insufficiency or renal insufficiency.
* 4.Has malignancy or other non-cardiac condition limiting life expectancy to \<1 years.
What they're measuring
1
a composite of death from cardiovascular causes or first hospitalization for heart failure
Timeframe: from baseline to one year
Trial details
NCT IDNCT06321094
SponsorThe First Affiliated Hospital with Nanjing Medical University